Indian Hepatitis C Therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD XX billion by 2028, exhibiting a CAGR of XX% during the forecast period.
In India there is a huge explosion of Hepatitis C. There are certain states which have seen a very great rise in the incidence of Hepatitis C and these states are Punjab, Haryana and parts of Uttar Pradesh, specifically western Uttar Pradesh. India is one of the fastest growing economies in the world today. Addressing our healthcare challenges is critical, both for our people individually, and for our country’s development. Hepatitis C, a disease affecting the liver, is a particular concern. Estimates suggest that, in India, anywhere between 6 and 12 million people are infected with the hepatitis C virus (HCV) – with 71 million people affected worldwide.
Growing healthcare costs coupled with the decline in R&D activities and Medicare budgets are some of the key factors affecting the profitability of players and impact the market dynamics to a great extent. Other factors are growing awareness pertaining to the availability of generic drugs is also expected to increase the treatment rate and improve overall healthcare outcomes. Increase in the usage of unsterilized equipment and infected syringes, medication errors, and transfusion of infectious blood are leading to an increase in the incidence of viral diseases. The number of government initiatives are increasing towards immunization. The government across different countries are providing facilities such as free vaccinations at a comparatively low cost. Government has also introduced various awareness schemes and plans to immunize people against Hepatitis C which is anticipated to boost the growth of the market.